Membrane tumor necrosis factor-alpha (TNF-alpha) expressed on HTLV-I-infected T cells mediates a costimulatory signal for B cell activation - Characterization of membrane TNF-alpha

被引:61
作者
Higuchi, M
Nagasawa, K
Horiuchi, T
Oike, P
Ito, Y
Yasukawa, M
Niho, Y
机构
[1] SAGA MED SCH,DEPT INTERNAL MED,SAGA 849,JAPAN
[2] KYUSHU UNIV,DEPT PHARMACOL,FAC MED,FUKUOKA 81282,JAPAN
[3] EHIME UNIV,FAC MED,DEPT INTERNAL MED 1,SHIGENOBU,EHIME 79102,JAPAN
来源
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY | 1997年 / 82卷 / 02期
关键词
D O I
10.1006/clin.1996.4291
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The 26-kDa membrane tumor necrosis factor-alpha (TNF-alpha) expressed on activated CD4(+) T cells is a novel candidate for the functional membrane molecule in T-B cell interactions. We found that normal human T cells, when infected with human T cell lymphotropic virus type I (HTLV-I) in vitro, were induced to express the 26-kDa membrane TNF-alpha. The infected T cells, through this molecule, activated autologous E cells to produce immunoglobulin (Ig)RI in a contact-dependent manner, which was partially inhibited by anti-TNF-alpha antibody (Ab). IgG synthesis was not stimulated, however, probably because of lack of CD40 ligand expression on the infected T cells, Anti-TNF-alpha Ab treatment stimulated the secretion of interleukin (IL)-2 and interferon gamma (IFN-gamma) in the infected T cells. These effects were not induced by anti-TNF receptor Ab treatment. Anti-TNF-alpha Ab also induced the elevation of intracellular calcium concentration in the infected T cells. These results suggest that T cells expressing membrane TNF-alpha can be directly stimulated through this molecule. Thus, it is suggested that the 26-kDa membrane TNF-alpha alpha on HTLV-I-infected T cells plays a role in polyclonal B cell activation and may be involved in the pathogenesis of some HTLV-I-associated diseases. Additionally, our results suggest a novel mechanism by which cytokine production can be modulated in these T cells through membrane TNF-alpha on their surface. (C) 1997 Academic Press.
引用
收藏
页码:133 / 140
页数:8
相关论文
共 35 条
[1]   THE CD40 LIGAND, GP39, IS DEFECTIVE IN ACTIVATED T-CELLS FROM PATIENTS WITH X-LINKED HYPER-IGM SYNDROME [J].
ARUFFO, A ;
FARRINGTON, M ;
HOLLENBAUGH, D ;
LI, X ;
MILATOVICH, A ;
NONOYAMA, S ;
BAJORATH, J ;
GROSMAIRE, LS ;
STENKAMP, R ;
NEUBAUER, M ;
ROBERTS, RL ;
NOELLE, RJ ;
LEDBETTER, JA ;
FRANCKE, U ;
OCHS, HD .
CELL, 1993, 72 (02) :291-300
[2]   THE 26-KD TRANSMEMBRANE FORM OF TUMOR-NECROSIS-FACTOR-ALPHA ON ACTIVATED CD4+ T-CELL CLONES PROVIDES A COSTIMULATORY SIGNAL FOR HUMAN B-CELL ACTIVATION [J].
AVERSA, G ;
PUNNONEN, J ;
DEVRIES, JE .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (06) :1575-1585
[3]   IDENTITY OF TUMOR NECROSIS FACTOR AND THE MACROPHAGE-SECRETED FACTOR CACHECTIN [J].
BEUTLER, B ;
GREENWALD, D ;
HULMES, JD ;
CHANG, M ;
PAN, YCE ;
MATHISON, J ;
ULEVITCH, R ;
CERAMI, A .
NATURE, 1985, 316 (6028) :552-554
[4]  
CASTLE BE, 1993, J IMMUNOL, V151, P1777
[5]   ANTITUMOR NECROSIS FACTOR MODULATES ANTI-CD3-TRIGGERED T-CELL CYTOKINE GENE-EXPRESSION IN-VIVO [J].
FERRAN, C ;
DAUTRY, F ;
MERITE, S ;
SHEEHAN, K ;
SCHREIBER, R ;
GRAU, G ;
BACH, JF ;
CHATENOUD, L .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (05) :2189-2196
[6]   ION CHANNELS IN LEUKOCYTES [J].
GALLIN, EK .
PHYSIOLOGICAL REVIEWS, 1991, 71 (03) :775-811
[7]   PROCESSING OF TUMOR-NECROSIS-FACTOR-ALPHA PRECURSOR BY METALLOPROTEINASES [J].
GEARING, AJH ;
BECKETT, P ;
CHRISTODOULOU, M ;
CHURCHILL, M ;
CLEMENTS, J ;
DAVIDSON, AH ;
DRUMMOND, AH ;
GALLOWAY, WA ;
GILBERT, R ;
GORDON, JL ;
LEBER, TM ;
MANGAN, M ;
MILLER, K ;
NAYEE, P ;
OWEN, K ;
PATEL, S ;
THOMAS, W ;
WELLS, G ;
WOOD, LM ;
WOOLLEY, K .
NATURE, 1994, 370 (6490) :555-557
[8]  
GESSAIN A, 1985, LANCET, V2, P407
[9]   THE TRANSMEMBRANE FORM OF TUMOR-NECROSIS-FACTOR IS THE PRIME ACTIVATING LIGAND OF THE 80 KDA TUMOR-NECROSIS-FACTOR RECEPTOR [J].
GRELL, M ;
DOUNI, E ;
WAJANT, H ;
LOHDEN, M ;
CLAUSS, M ;
MAXEINER, B ;
GEORGOPOULOS, S ;
LESSLAUER, W ;
KOLLIAS, G ;
PFIZENMAIER, K ;
SCHEURICH, P .
CELL, 1995, 83 (05) :793-802
[10]  
JUMPER MD, 1995, J IMMUNOL, V155, P2369